R&D Finance vs Venture Debt: Which One Is Right for Your Stage?

By Alex Knight, Founder and CEO, Advanced

Both R&D financing and venture debt are described as non-dilutive. Both sit outside equity. Both can extend your runway without touching the cap table. Beyond those three things, they work very differently, and using the wrong one for your situation can be expensive.

The verdict upfront: venture debt is the right tool when you have revenue traction, a VC on your cap table, and you want to extend runway after a raise. R&D financing is the right tool when you have eligible R&D spend accruing and a refund that isn't here yet. They solve different problems. The choice isn't about which one is better. It's about which one matches your actual situation.

Here's the full comparison.

What Venture Debt Is

Venture debt is a loan made to venture-backed startups, typically structured as a term loan with a fixed repayment schedule. It's almost always offered alongside or shortly after an equity raise. The equity raise is what gives the lender confidence the company has institutional backing and a credible path forward.

 In Australia, venture debt providers include specialist lenders, some major banks with innovation arms, and international lenders operating locally.

The structure has three standard components: principal, interest, and warrants. The principal is the loan amount, repaid over the term. Interest is charged monthly, typically between 8-14% per annum. Warrants are the equity component: a small number of options to purchase shares, usually representing 0.5-2% of the loan amount in equity value. The warrant is how the lender participates in upside on a loan that carries more risk than a traditional debt product.

Venture debt typically covers 20-30% of the most recent equity raise. If you raised $5 million, you might access $1-1.5 million in venture debt alongside it.

What R&D Financing Is

R&D financing advances a company's anticipated R&D Tax Incentive refund before the ATO processes the claim. The security is the refund itself: the government's commitment to return 43.5 cents for every dollar of eligible spend for companies with aggregated turnover under $20 million.

The structure is simpler than venture debt. The facility is sized based on the anticipated refund. Advanced typically advances up to 80% of that expected refund. The facility is repaid when the ATO refund arrives, in a single payment, not monthly instalments. There are no warrants. No monthly interest payments that draw down your cash position. No equity component.

The cost is a financing fee based on the size of the facility and the duration, approximately 1.38% per month. On a $200,000 facility over six months, that's approximately $16,500 in total cost.

‍

‍

Who Venture Debt Works For

Venture debt is well-suited to a specific profile: a VC-backed startup that has just closed an equity round, has some revenue traction (or a credible near-term revenue story), and wants to extend runway without issuing more equity.

The logic is sound in this context. If you've just raised $5 million at a $20 million valuation and you expect to raise again in 18 months at $40 million, issuing equity today to bridge a 6-month gap is expensive. Venture debt at $1 million costs you roughly $120,000-140,000 in interest plus warrant dilution. Issuing equity for the same $1 million at today's valuation costs you 5% of the company permanently. The maths favours venture debt.

But venture debt only works this way under specific conditions. You need a lead investor. Venture debt providers follow equity, they don't lead. You need revenue, or a very strong story about why revenue is imminent. You need covenants you can live with: venture debt agreements typically include minimum cash requirements, revenue targets, and restrictions on further borrowing. And you need to be comfortable with monthly repayments drawing down your cash position regardless of business performance.

Who R&D Financing Works For

R&D financing is suited to a different profile: a company spending on eligible R&D that has a refund accruing and can't wait 9-12 months for it to arrive.

The profile of the typical Advanced client looks like this. They're spending $300,000-$1 million on eligible R&D activity in a financial year. They have a team doing real experimental work: product development, hardware prototyping, clinical trials, field trials, software with genuine technical uncertainty. They're either pre-revenue or in early revenue, which means venture debt isn't accessible to them. And they have a refund building in the pipeline that isn't going to arrive until October at the earliest.

R&D financing doesn't require a VC on your cap table. It doesn't require revenue. It doesn't require monthly repayments. The only qualification is eligible R&D spend accruing under the RDTI program and the refund that comes from it.

For companies at this stage, venture debt isn't usually an option anyway. R&D financing fills exactly the gap it leaves.

The Cost Comparison in Practice

This comparison works best with real numbers.

Say you need $200,000 of working capital for six months. You have two options: venture debt or R&D financing. Your eligible R&D spend is $600,000, generating a $261,000 anticipated refund.

Venture debt at $200,000:

Interest at 10% per annum over six months: $10,000. Monthly repayment of approximately $33,333 plus interest draws down cash position continuously. Warrants representing 1% of the loan in equity: approximately $2,000 at a $20 million valuation, but permanent dilution. Total cost: approximately $12,000 in cash plus permanent equity component. Monthly cash drag during the facility period is significant.

R&D financing at $200,000:

Financing fee at 1.38% per month over six months: $16,560. Single repayment when ATO refund arrives. No monthly cash drain. No warrants. No equity. Total cost: $16,560. Monthly cash drag during the facility period: zero.

The financing fee on R&D financing is higher on an annualised basis than a venture debt interest rate. But that comparison misses two things. First, venture debt typically requires warrants, adding permanent dilution that doesn't appear in the interest rate. Second, venture debt requires monthly repayments that reduce cash available for the build. R&D financing has no monthly cash impact during the facility period. The repayment happens in a single event when the ATO refund lands.

For a pre-revenue company, the monthly repayment difference alone often makes R&D financing the more practical option, regardless of the rate comparison.

The Warrants Question

Venture debt warrants are worth examining carefully because they're easy to underestimate at the time of signing.

A $1 million venture debt facility with 1% warrant coverage at a $20 million valuation gives the lender options over $200,000 of equity. That's manageable. But the options typically vest at a fixed strike price tied to the current round. If the company raises its next round at $60 million, the lender's $200,000 of options becomes worth significantly more. The warrant is structured to let the lender participate in that upside.

Over multiple venture debt facilities across a company's life, warrant dilution accumulates. By the time a company reaches Series B or C, the cumulative venture debt warrant dilution can be meaningful: 3-5% of total equity across several facilities. It doesn't feel large at any individual signing, but it compounds.

R&D financing has no warrants. No equity component. The cap table looks identical before and after the facility is repaid.

When to Use Each One

Use R&D financing when:

• You have eligible R&D spend accruing and a refund building
• You're pre-revenue or early revenue and venture debt isn't accessible
• You want to avoid monthly repayments drawing down cash during the build
• Your priority is protecting the cap table completely

Use venture debt when:

• You've just closed an equity round and want to extend runway
• You have revenue traction and a VC lead
• You're comfortable with monthly repayments against cash
• The equity raise gave you the covenants headroom to take on debt

Use both when:

• Your R&D spend generates a refund large enough to access via R&D financing, and your revenue traction qualifies you for venture debt alongside it
• You want maximum runway extension and can service both structures simultaneously

For most companies reading this article, the choice isn't one or the other. It's a question of which is accessible right now. R&D financing is available to earlier-stage companies that venture debt won't touch. If you have eligible R&D spend, that's where to start.